Topical photodynamic therapy (PDT) is widely used for actinic keratoses (AK), Bowen’s disease (BD) and superficial basal cell carcinoma (BCC), with a strong evidence‐base regarding efficacy and high levels of patient satisfaction. The British Association of Dermatologists published standards for PDT service delivery to ensure appropriate clinical governance, training and practices. Topical PDT involves application of a photosensitiser pro‐drug (5‐aminolaevulinic acid or methylaminolevulinate) and subsequent visible light exposure, generally using red LED light (conventional PDT; cPDT). This initiates PDT phototoxicity, usually resulting in discomfort, pain and inflammation. Daylight PDT (dPDT) is also increasingly used for AK with high levels of tolerance.